Pulmatrix - press releases https://ir.pulmatrix.com/ <a href="https://pulmatrix.reportablenews.com/pr/pulm-positive-top-line-results-in-ph-1-pulmazole-trial">Pulmatrix Announces Positive Top-Line Preliminary Results from Part 3 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole</a> https://ir.pulmatrix.com/2018-07-17-Pulmatrix-Announces-Positive-Top-Line-Preliminary-Results-from-Part-3-of-the-3-Part-Phase-1-1b-Clinical-Trial-of-Pulmazole-an-Inhaled-Dry-Powder-iSPERSE-TM-Formulation-of-Itraconazole Single dose of Pulmazole safe and well tolerated in subjects with asthma Tue, 17 Jul 2018 09:00:00 -0400 https://ir.pulmatrix.com/2018-07-17-Pulmatrix-Announces-Positive-Top-Line-Preliminary-Results-from-Part-3-of-the-3-Part-Phase-1-1b-Clinical-Trial-of-Pulmazole-an-Inhaled-Dry-Powder-iSPERSE-TM-Formulation-of-Itraconazole Pulmatrix Announces Positive Top-Line Results from Parts 1 and 2 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole https://ir.pulmatrix.com/2018-06-25-Pulmatrix-Announces-Positive-Top-Line-Results-from-Parts-1-and-2-of-the-3-Part-Phase-1-1b-Clinical-Trial-of-Pulmazole-an-Inhaled-Dry-Powder-iSPERSE-TM-Formulation-of-Itraconazole All doses were well tolerated in normal healthy volunteers in Parts 1 and 2 at up to 35 mg of itraconazole, the maximal dose planned Mon, 25 Jun 2018 08:30:00 -0400 https://ir.pulmatrix.com/2018-06-25-Pulmatrix-Announces-Positive-Top-Line-Results-from-Parts-1-and-2-of-the-3-Part-Phase-1-1b-Clinical-Trial-of-Pulmazole-an-Inhaled-Dry-Powder-iSPERSE-TM-Formulation-of-Itraconazole Pulmatrix Announces Publication of Results from a Phase 1 Pharmacodynamic Study of PUR0200 in COPD Patients https://ir.pulmatrix.com/2018-06-13-Pulmatrix-Announces-Publication-of-Results-from-a-Phase-1-Pharmacodynamic-Study-of-PUR0200-in-COPD-Patients Data published in the British Journal of Clinical Pharmacology demonstrate that PUR0200 achieves similar improvements in lung function to Spiriva® HandiHaler® at significantly lower doses Wed, 13 Jun 2018 09:35:00 -0400 https://ir.pulmatrix.com/2018-06-13-Pulmatrix-Announces-Publication-of-Results-from-a-Phase-1-Pharmacodynamic-Study-of-PUR0200-in-COPD-Patients Pulmatrix Announces Approval of Proposals Submitted to Company's Stockholders https://ir.pulmatrix.com/2018-06-07-Pulmatrix-Announces-Approval-of-Proposals-Submitted-to-Companys-Stockholders No Imminent Plan to Effect Reverse Stock Split Thu, 07 Jun 2018 09:30:00 -0400 https://ir.pulmatrix.com/2018-06-07-Pulmatrix-Announces-Approval-of-Proposals-Submitted-to-Companys-Stockholders Pulmatrix selected to present company profile at the 2018 Respiratory Innovation Summit in San Diego https://ir.pulmatrix.com/2018-05-17-Pulmatrix-selected-to-present-company-profile-at-the-2018-Respiratory-Innovation-Summit-in-San-Diego Company will also present pre-clinical data on RV1162 (PUR1800) at the affiliated American Thoracic Society 2018 International Conference in San Diego Thu, 17 May 2018 09:35:00 -0400 https://ir.pulmatrix.com/2018-05-17-Pulmatrix-selected-to-present-company-profile-at-the-2018-Respiratory-Innovation-Summit-in-San-Diego